Covered recipient · General Payments record
AMIR SHARAFI
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$896.03
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $364.98 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $59.72 | 3 |
| Lilly USA, LLC | $52.52 | 2 |
| Novo Nordisk AS | $51.31 | 2 |
| ABBVIE INC. | $47.16 | 2 |
| Exact Sciences Corporation | $35.65 | 1 |
| PFIZER INC. | $29.93 | 2 |
| Medtronic, Inc. | $21.88 | 1 |
| Noven Therapeutics, LLC | $20.06 | 1 |
| GlaxoSmithKline, LLC. | $18.68 | 1 |
| Antares Pharma, Inc. | $14.75 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $13.32 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.89 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106073694 | CMS |
| ABBVIE INC. | $26.27 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106073696 | CMS |
| Amgen Inc. | $19.33 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117380528 | CMS |
| Amgen Inc. | $21.91 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111704632 | CMS |
| Amgen Inc. | $18.48 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111704634 | CMS |
| Antares Pharma, Inc. | $14.75 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146485029 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $13.32 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086170886 | CMS |
| Exact Sciences Corporation | $35.65 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114890901 | CMS |
| GlaxoSmithKline, LLC. | $18.68 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116313041 | CMS |
| Lilly USA, LLC | $27.54 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136026522 | CMS |
| Lilly USA, LLC | $24.98 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136030774 | CMS |
| Medtronic, Inc. | $21.88 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119423017 | CMS |
| Noven Therapeutics, LLC | $20.06 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1084818178 | CMS |
| Novo Nordisk Inc | $20.90 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096647209 | CMS |
| Novo Nordisk Inc | $30.41 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096911762 | CMS |
| PFIZER INC. | $15.38 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132131725 | CMS |
| PFIZER INC. | $14.55 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131144930 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.